Structure based design of peptidomimetic inhibitors of the MLL1-WDR5 interaction
Başlık çevirisi mevcut değil.
- Tez No: 402958
- Danışmanlar: DR. SHAOMENG WANG
- Tez Türü: Doktora
- Konular: Biyokimya, Biochemistry
- Anahtar Kelimeler: Belirtilmemiş.
- Yıl: 2012
- Dil: İngilizce
- Üniversite: University of Michigan
- Enstitü: Yurtdışı Enstitü
- Ana Bilim Dalı: Belirtilmemiş.
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 110
Özet
Özet yok.
Özet (Çeviri)
MLL1 is a histone-3 lysine-4 (H3K4) methyltransferase, which is misregulated in patients with leukemia and linked with tumorigenicity through upregulation of the target genes HoxA9 and Meis-1. Suppressing expression of these genes by targeting the catalytic activity of MLL1 may be a novel approach in cancer therapy. Methylation of H3K4 by MLL1 requires formation of a core complex consisting of MLL1, WDR5, RbBP5 and ASH2L. The interaction between MLL1 and WDR5 in this complex is essential for its catalytic activity and disruption of the MLL1-WDR5 interaction may provide significant therapeutic benefit to suppress target gene expression and thus tumorigenesis. In this study, the design of peptidomimetic inhibitors that can disrupt the interaction between MLL1 and WDR5 is presented. Starting from a 12mer peptide, the tripeptide -CO-ARA-NH- in MLL1 was identified as the minimal motif for binding to WDR5. Systematic modifications to the Ac-ARA-NH2 tripeptide were performed to elucidate the interaction of WDR5 with its ligands, and a number of peptidomimetic compounds with Ki < 1 nM for WDR5 were developed. These compounds were also demonstrated to effectively inhibit the catalytic activity of the reconstituted MLL1 core complex in vitro. Further modifications to improve cellular permeability of the peptidomimetic inhibitors led to design of MM-101 and MM-102, which have subnanomolar binding affinities for WDR5. Crystal structures of MM-101 and MM-102 provide insight for further development of inhibitors. MM-102 inhibits the interaction between MLL1 and WDR5 in vitro, and reduces expression of HoxA9 and Meis-1 genes in MLL1-AF9 transduced bone marrow cells. These findings, together with the selective growth inhibition of leukemia cell lines with MLL1 fusion proteins upon treatment with MM-102, suggest that inhibitors targeting the MLL1-WDR5 interaction have a therapeutic potential in cancer therapy.
Benzer Tezler
- Sanal tarama ve çok boyutlu moleküler modelleme yöntemleri ile p53-MDM2 potansiyel inhibitörlerinin belirlenmesi
Identification of p53-MDM2 potential inhibitors with virtual screening and multidimensional molecular modeling methods
GÜLŞAH AYDIN
Doktora
Türkçe
2020
Kimyaİstanbul Teknik ÜniversitesiKimya Ana Bilim Dalı
PROF. DR. MİNE YURTSEVER
PROF. DR. SERDAR DURDAĞI
- Kolon kanseri teşhisine yönelik benzotiyazol türevlerinin geliştirilmesi ve sentezi
Development and synthesis of benzothiazole derivatives for colon cancer diagnosis
ESRA UYSAL
Yüksek Lisans
Türkçe
2020
Kimyaİstanbul Teknik ÜniversitesiKimya Ana Bilim Dalı
DR. ÖĞR. ÜYESİ ONUR ALPTÜRK
DR. ÖZGÜR YILMAZ
- Synthesis of peptidomimetic based imaging agents against lung cancer
Peptidomimetik tabanlı kanser görüntüleme ajanlarının sentezlenmesi
GÖZDE SARIOĞLU
Yüksek Lisans
İngilizce
2019
Kimyaİstanbul Teknik ÜniversitesiKimya Ana Bilim Dalı
YRD. DOÇ. ONUR ALPTÜRK
DR. ÖZGÜR YILMAZ
- Meme kanserinin PD-L1 proteinleri aracılığıyla potansiyel teşhisine yönelik yeni nesil benzotiyazol türevlerinin sentezi ve karakterizasyonu
Synthesis and characterization of new generation benzothiazole derivatives for potential diagnosis of breast cancer through PD-L1 proteins
BÜŞRA YAZICI
Yüksek Lisans
Türkçe
2020
Kimyaİstanbul Teknik ÜniversitesiKimya Ana Bilim Dalı
DR. ÖĞR. ÜYESİ ONUR ALPTÜRK
DR. ÖZGÜR YILMAZ
- Palplanş perdeli derin kazı destek sistemlerinde zemin kesiti ve tasarım yönteminin etkisi
Effect of soil profile and design method on deep excavation support systems with sheet piles
EMRE FENERCİ
Yüksek Lisans
Türkçe
2010
İnşaat MühendisliğiSakarya Üniversitesiİnşaat Mühendisliği Ana Bilim Dalı
YRD. DOÇ. DR. AŞKIN ÖZOCAK